A novel digital health intervention to improve patient engagement to stimulants in adult ADHD in the primary care setting: Preliminary findings from an open label study

2020 ◽  
Vol 291 ◽  
pp. 113158
Author(s):  
Joseph Biederman ◽  
Ronna Fried ◽  
Maura DiSalvo ◽  
Haley Driscoll ◽  
Allison Green ◽  
...  
Keyword(s):  
Primary Care ◽  
Patient Engagement ◽  
Adult Adhd ◽  
Care Setting ◽  
Primary Care Setting ◽  
Digital Health ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Improve Patient

Do scribes improve patient satisfaction in the primary care setting?

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jonathan Dutt ◽  
Pooja Sheth-Dutt ◽  
Michal Dynda
Keyword(s):  
Primary Care ◽  
Patient Satisfaction ◽  
Care Setting ◽  
Primary Care Setting ◽  
Improve Patient Satisfaction ◽  
Improve Patient

scholarly journals Patient Engagement, Access to Care, and Perceptions of Competing Priorities in the VA Primary Care Setting

2019 ◽  
Vol 34 (10) ◽  
pp. 1971-1972 ◽  
Author(s):  
Richard SoRelle ◽  
Judy A. Shea ◽  
Becky Shasha ◽  
Shimrit Keddem ◽  
Judith A. Long ◽  
...  
Keyword(s):  
Primary Care ◽  
Access To Care ◽  
Patient Engagement ◽  
Care Setting ◽  
Primary Care Setting ◽  
Competing Priorities

scholarly journals Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension

2020 ◽  
pp. 108705471989685
Author(s):  
Margaret D. Weiss ◽  
Ann C. Childress ◽  
Graeme A.E. Donnelly
Keyword(s):  
Adult Adhd ◽  
Rating Scale ◽  
Least Square ◽  
Blind Study ◽  
Double Blind Study ◽  
Efficacy And Safety ◽  
Open Label ◽  
Double Blind ◽  
Open Label Study ◽  
Label Study

Objective: To evaluate the efficacy and safety of a 16-hr multilayer-release methylphenidate (PRC-063) in a community-based adult ADHD population. Method: In a double-blind study, 375 participants were randomized to one of four fixed doses of PRC-063 or placebo. The primary outcome was the ADHD-Rating Scale-5 (RS). The first 50% of double-blind completers were invited to participate in a 6-month dose-optimized open-label study to assess response and safety. Results: In total, 333 participants completed the double-blind trial; 184 entered the open-label study. PRC-063 produced greater symptom reduction in ADHD-RS-5 total score from baseline compared with placebo in the double-blind study (least-square [LS] mean = −4.7 [−7.7, −1.6], p = .003). The most frequent adverse events were headache, insomnia, and decreased appetite. No significant sleep quality impact was observed ( p = .123). Significant improvements in ADHD-RS-5 scores from baseline continued through the open-label study ( p < .0001), coincident with dose optimization. Conclusion: PRC-063 was well tolerated and significantly improved ADHD symptomatology in adults.

scholarly journals Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care

2018 ◽  
Vol 24 (6) ◽  
pp. 293-303 ◽  
Author(s):  
Philippe Castera ◽  
Edmund Stewart ◽  
Josef Großkopf ◽  
Carlos Brotons ◽  
Maiken Brix Schou ◽  
...  
Keyword(s):  
Primary Care ◽  
Alcohol Dependence ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Routine Treatment
Sign in / Sign up

Export Citation Format

Share Document